Improving selective androgen receptor modulator discovery and preclinical evaluation

Area of Science:

• Pharmacology
• Molecular Biology
• Drug Discovery

Background:

• Selective Androgen Receptor Modulators (SARMs) are a novel pharmaceutical class with potential clinical applications.
• Current understanding of SARM selectivity at the molecular level is limited, complicating drug development.
• This limitation impedes the effective discovery and preclinical assessment of SARMs.

Purpose of the Study:

• To review the current status of SARM discovery and preclinical evaluation.
• To examine the molecular mechanisms governing Androgen Receptor (AR) selectivity.
• To discuss how enhanced molecular insights can improve SARM development and safety.

Main Methods:

• Literature review of SARM discovery and preclinical evaluation strategies.
• Analysis of current understanding of molecular mechanisms controlling AR selectivity.
• Discussion of future research directions and their potential impact.

Main Results:

• The SARM field has progressed rapidly but lacks a strong molecular basis for discovery and evaluation.
• The current definition of selectivity is narrow, potentially overlooking effects on various androgen-responsive tissues.
• This narrow view may lead to unforeseen adverse effects with long-term SARM use.

Conclusions:

• Investment in basic research on AR molecular selectivity is crucial.
• This research can accelerate the development of next-generation, safer SARMs.
• Improved SARM selectivity could expand their therapeutic applications for a wider range of conditions.